Skip to main content
. 2023 Jan 20;8:1. doi: 10.1038/s41525-022-00346-5

Fig. 1. Progression-free survival (PFS) among 18 patients with pancreatic cancer who received matched therapy.

Fig. 1

a PFS in 18 patients. b PFS in 5 patients who received targeted therapy as first line versus 13 patients who received it as ≥2nd line. c PFS in 11 patients with matching score ≥50% versus 7 patients with matching score <50%. CI confidence interval, PFS progression-free survival.